Evidence map›Paper›PMID 35033084›Full record

ArticleCancer cell international2022

MiR-937-3p promotes metastasis and angiogenesis and is activated by MYC in lung adenocarcinoma.

Zijian Ma, Ganyi Chen, Yiqian Chen, Zizhang Guo, Hao Chai, Yu Tang, Lin Zheng, Ke Wei, Chunfeng Pan, Zhifei Ma and 2 more

Abstract read
In one paragraph

Article in Cancer cell international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Hsa_circ_0102899 promotes epithelial-mesenchymal transition in non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zijian Ma *Department of Thoracic Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Ganyi Chen *Department of Thoracic Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Yiqian ChenDepartment of Thoracic Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Zizhang GuoDepartment of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Hao ChaiDepartment of Thoracic Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Yu TangDepartment of Thoracic Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Lin ZhengDepartment of Thoracic Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Ke WeiDepartment of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Chunfeng PanDepartment of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zhifei MaDepartment of Thoracic Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Yang XiaDepartment of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. xiayang-1019@njmu.edu.com.ORCID http://orcid.org/0000-0003-0479-1615
Aiping ZhangDepartment of Thoracic Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. apzhdoc68@163.com.

Funding

National Outstanding Youth Science Fund Project of National Natural Science Foundation of China 81902328/81702262
6 · The paper itself

Abstract

backgroundNon-small cell lung cancer (NSCLC) is still one of the diseases with the highest mortality and morbidity, and lung adenocarcinoma (LUAD) accounts for more than half of all NSCLC cases in most countries. miRNA can be used as a potential biological marker and treatment for lung adenocarcinoma. However, the effect of miR-937-3p to the invasion and metastasis of LUAD cells is not clear.

methodsmiRNA microarray is used to analyze the expression of miRNA in lung adenocarcinoma tissue. Transwell migration, Wound-healing assay and Western blot analysis are used to analyze cell migration, invasion and epithelial-mesenchymal transition (EMT) capabilities. Tube formation is used to assess angiogenesis ability. In addition, dual luciferase reporter gene detection is used to identify the potential binding between miRNA and target mRNA. In vivo experiments were performed on male NOD/SCID nude mice by tail vein injection to establish a transplanted tumor model. The CHIP experiment is used to verify the transcription factors of miRNA.

resultIn our study, miR-937-3p was high-regulated in LUAD cell lines and tissues, and its expression level was related to tumor progression. We found that miR-937-3p high-expression has an effect on cell invasion and metastasis. In molecular mechanism, miR-937-3p causes SOX11 reduction by directly binding to the 3'-UTR of SOX11.In addition, MYC affects miR-937-3p transcription by binding to its promoter region.

conclusionsOur research shows that miR-937-3p is mediated by MYC and can control the angiogenesis, invasion and metastasis of LUAD by regulating SOX11, thereby promoting the progress of LUAD. We speculate that miR-937-3p can be used as a therapeutic target and potential biomarker for LUAD.

Indexed as

EMTLung adenocarcinomamiR-937-3pMYCSOX11

Identifiers

PMID35033084
PMCPMC8761314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.